dc.contributor.author |
Alisher M. Urinov, T Ilkhom O. Otajonov, Dilafruz B. Akhmedova |
|
dc.date.accessioned |
2023-02-17T10:47:24Z |
|
dc.date.available |
2023-02-17T10:47:24Z |
|
dc.date.issued |
2023-02 |
|
dc.identifier.issn |
2515-8260 |
|
dc.identifier.uri |
http://repository.tma.uz/xmlui/handle/1/6355 |
|
dc.description.abstract |
The frequency of cirrhosis is about 20–40 cases per 100,000 populations, and
this indicator is steadily increasing. At present, it is one of the six main causes of death at the
age of 35–60 years in economically developed countries. Foreign and domestic scientists are
working on the development and synthesis of new drugs of chemical and natural origin for
the treatment and prevention of liver diseases of various origins, in particular liver cirrhosis.
Many studies have shown an important pathogenic role in the occurrence and progression of
some liver diseases with changes in the intestinal microbiota. Therefore, antibiotics,
prebiotics and probiotics are an effective treatment for liver diseases, which can correct the
intestinal microbiota. |
en_US |
dc.language.iso |
other |
en_US |
dc.subject |
liver disease, probiotics, liver cirrhosis, treatment |
en_US |
dc.title |
THE ROLE OF PROBIOTICS IN LIVER CIRROSIS |
en_US |
dc.type |
Article |
en_US |